Skip to main content

Charles River to buy CiToxLab

Charles River Laboratories (CRL) has agreed to acquire CiToxLab in a €448 million merger that will create the largest player in the early stage CRO space for the pharmaceuticals industry. The deal is expected to close in Q2, subject to labour consultations, regulatory requirements and customary closing conditions.

Four become one in Seqens

Pharmaceutical synthesis and speciality ingredients firm Novacap has announced that it is combining all of its CDMO subsidiaries

Cambrex expands in analytics

API and finished dosage form manufacturer Cambrex is investing $1 million at its site in High Point, North Carolina, in response to a growing number of new projects.

Subscribe to Pharmaceuticals